

Blue, Stratagene) and colonies containing the correct DNA inserts were selected and amplified. Closed circular plasmid DNA was purified by CsCl density centrifugation. The DNA (1 μ g) was denatured and hybridized to synthetic deoxyribonucleotide primers (15-mers). The DNA sequence was determined by the chain-termination method of Sanger *et al.* (11) using the Sequenase reaction mixtures recommended by the supplier.

In Vitro Translation of T-Cell PTPase mRNA. The Bluescript plasmid containing the T-cell cDNA was made linear by *Hind*III restriction endonuclease digestion. mRNA was synthesized *in vitro* from 1 μ g of plasmid DNA using the T7 polymerase promoter and Stratagene's assay condition. The DNA was degraded with DNase I and the RNA was purified. The mRNA (1 μ g) was added to 20 μ l of a rabbit reticulocyte

translation system in the presence of [³⁵S]methionine and protein synthesis was allowed to proceed for 30 min. The control reaction mixture contained mRNA produced from linearized vector. The products were analyzed on a 10% SDS/polyacrylamide gel (12) and subjected to autoradiography for 18 hr.

Northern Blot Analysis. Total RNA was extracted (13) from monkey brain, spleen, and thymus; human RNA was from placenta and T cells. Poly(A)⁺ mRNA was purified by oligo(dT) column chromatography as described (10). Poly(A)⁺ mRNA (10 μ g) from brain, spleen, thymus, and placenta and 20 μ g of the total T-cell mRNA were subjected to Northern blot analysis using ³²P-labeled cDNA insert from the T-cell clone as a probe. The hybridization conditions were the same as those described for the screening of the library except that




FIG. 1. Sequencing strategy, nucleotide, and deduced amino acid sequence of human T-cell cDNA T-cell PTPase. The predicted amino acid sequence of the open reading frame is shown below the nucleotide sequence. The oligonucleotide sequences used for screening the library are indicated by dots [e.g., between nucleotides 425 and 479 (probe 1), and 689 and 737 (probe 2)]. The TAA stop codon is located at nucleotide 1306 followed by a 3' untranslated end containing two possible polyadenylation sites AATAAA at 1521 and 1677. The schematic diagram below the nucleotide sequence depicts the sequencing strategy used. Open bar, open reading frame; solid bar, 3' untranslated end. Arrows indicate the length of sequence obtained from different sequencing oligonucleotide primers. E, *Eco*RI; H, *Hind*III; S, *Sst* I; X, *Xba* I. The scale at the bottom represents 200 nucleotides (in kbp).

the blot was washed in $0.1 \times$ SSC/ 0.2% SDS at 50°C . The gel was exposed to film for 3 days with an intensifier screen at -70°C .

Southern Blot Analysis. Human genomic DNA was cleaved with the restriction endonucleases *Bam*HI, *Eco*RI, and *Hin*dIII. The blot was hybridized to the labeled insert of the cDNA and washed as described for the Northern blot analysis and subjected to autoradiography for 3 days with an intensifier screen at -70°C . It was then reprobbed with the labeled cDNA using the same hybridization conditions as above, but washed under less stringent conditions, such as $2 \times$ SSC/ 0.2% SDS and 45°C .

RESULTS

Isolation and DNA Sequence Analysis of a Human T-Cell cDNA Encoding an Isoform of Placenta PTPase 1B. Two synthetic ^{32}P -labeled oligonucleotides representing different segments of the low M_r placenta PTPase 1B were used as probes to screen duplicate plaque lifts containing 500,000 recombinant phage from a λ gt10 cDNA library prepared from human peripheral T-cell mRNA (8). Although many recombinant phage hybridized to each probe, only one overlapping positive clone bound to both oligonucleotides. Restriction enzyme analysis of the purified recombinant cDNA revealed a single *Eco*RI cDNA insert 2.3 kilobase pairs (kbp) long (Fig. 1). The entire nucleotide sequence of the *Eco*RI fragment was obtained in duplicate on both strands. The sequencing strategy is shown in Fig. 1; short regions of DNA sequence represented by the overlapping arrows were obtained with different primers in the extension reactions. Sequence analysis (Fig. 1) shows that the T-cell PTPase cDNA contains an open reading frame of 1305 nucleotides. A consensus sequence [CC(A)CCAUG(G)] for eukaryotic initiation sites described by Kozak (14) is found at nucleotides 56–64 encoding a putative initiator methionine. The open reading frame terminates with a TAA stop codon followed by 978 bp of 3' untranslated end. However, neither a polyadenylation site nor a 3' poly(A)⁺ tail was observed. There are two possible AATAAA polyadenylation signals (15) at sites 213 and 369 bp past the stop codon (nucleotides 1521–1526 and 1677–1682, respectively).

Identification of an Initiator Methionine Residue. mRNA was synthesized *in vitro* from the T7 polymerase promoter in the Bluescript vector in which the T-cell cDNA was subcloned. Using the rabbit reticulocyte lysate translation system, a protein product with an estimated M_r of 48,000 was produced (Fig. 2). Since its apparent M_r agreed closely with that predicted from the cDNA sequence, it is probable that the putative initiator methionine at nucleotide 61 is being recognized as a translation initiator codon in the *in vitro* system. The translation reaction was carried out in the presence of [^{35}S]methionine and the band of labeled protein was excised and counted. The amount of protein synthesized, estimated at 2.5 μg , was not sufficient to detect PTPase activity under our assay conditions (16).

The T-Cell cDNA Sequence Is Present in Other Tissues. Northern blot analysis of mRNA extracted from monkey brain, spleen, and thymus and human T cell and placenta reveals multiple bands of hybridization (Fig. 3). The most abundant transcript of ≈ 2.3 kb was found in all the above tissues, although the level of expression in brain was quite low. Comparison of the thymus poly(A)⁺ mRNA with the T-cell total mRNA shows at least a 20-fold enrichment of the transcript. The predominant message, whose precise length cannot be determined in the agarose gel, seems likely to represent the T-cell PTPase cDNA since the expected length of this transcript is at least 2.5 kb including a 200-base poly(A)⁺ tail (17).




FIG. 2. SDS/PAGE analysis of the ^{35}S -labeled protein following translation *in vitro* from T-cell PTPase mRNA. Capped mRNA ($1 \mu\text{g}$) synthesized from the T7 polymerase promoter in the Bluescript plasmid vector containing the T-cell cDNA (or the plasmid alone) was added to $25 \mu\text{l}$ of a rabbit reticulocyte *in vitro* translation system and incubated for 30 min at 30°C in the presence of [^{35}S]methionine. The extract ($10 \mu\text{l}$) was boiled with $20 \mu\text{l}$ of $2 \times$ sample buffer and a third of the sample was applied to a 10% SDS/polyacrylamide gel, according to Laemmli (12). The newly synthesized ^{35}S -labeled proteins were detected after 16 hr of autoradiography. Lanes: 1, control containing mRNA synthesized from the Bluescript vector DNA; 2, from vector containing T-cell PTPase cDNA. Molecular weight markers ($\times 10^{-3}$) are indicated by arrows and numbers.

The Northern blot also reveals other species of poly(A)⁺ mRNA that are of higher molecular weight than those described above. Poly(A)⁺ mRNA from the various tissues all have a hybridizing transcript at the 28S marker not observed in the total T-cell RNA; this 4.7-kb species could encode a high M_r transmembrane molecule related to CD45. Also, a very high molecular weight message (>7 kb) detected in all the poly(A)⁺ purified samples but not in total RNA could be due to LAR, which has a transcript of 8 kb (18), or other as yet unreported PTPases.

Relationship Between the T-Cell PTPase and the Low Molecular Weight Placenta Enzyme. The preceding article (1)




FIG. 3. Detection of the T-cell transcript in tissue. Ten micrograms of poly(A)⁺ mRNA from monkey brain, spleen, or thymus and from human placenta mRNA and $20 \mu\text{g}$ of total human T-cell RNA were subjected to electrophoresis in a 1% formaldehyde-agarose gel and transferred to nitrocellulose paper. The RNA blot was hybridized with ^{32}P -labeled cDNA insert from T-cell PTPase and subjected to autoradiography for 3 days. Br, brain; Sp, spleen; Th, thymus; Tc, T cell; Pl, placenta. The 28S and 18S ribosomal bands are indicated and correspond to 4.7- and 1.9-kb transcript lengths, respectively.

adhesion molecule N-CAM (26). The existence of multiple forms may suggest differences in substrate specificity and function.

The low M_r placenta enzyme displays unusually high specific activity and affinity toward artificial substrates (16). By contrast, CD45 has only 1% of the activity of PTPase 1B under our standard assay conditions (24). This could be due to loss of activity during purification, differing substrate specificity, lack of a ligand binding to the external domain or, as in the case of the protein tyrosine kinases, to the fact that the receptor-linked forms seem to be intrinsically less active than their cytoplasmic counterparts (24). With 65% sequence identity between the two low M_r proteins and up to 85% sequence similarity within the 236-residue core described in the preceding article (1) as shown in Fig. 4, it could be anticipated that the T-cell PTPase protein would exhibit similar enzymatic activity to the placenta enzyme. However, these two proteins display significant differences in their carboxyl termini. The placenta enzyme is smaller (M_r , 37,000 vs. 48,000) and ends with a segment in which 10 of 21 residues are prolyl. The T-cell protein has an extension (M_r , \approx 11,000) with a highly charged segment (Lys-284 to Lys-390) followed by a region of 25 uncharged residues. It will be interesting to determine whether this C-terminal extension possesses some regulatory function such as exerting a negative influence on enzyme activity. Cleavage of such a structure in a posttranslational event or during purification might derepress the enzyme and contribute to the high specific activity of PTPase 1B. Alternatively, it would serve to localize the protein in specific intracellular elements or compartments.

The role of low M_r PTPases in cell signaling, growth, and transformation is not known. They may be responsible for ensuring the transient nature of tyrosine phosphorylation events in response to certain external stimuli. Considering the discrepancy between the activity of the protein tyrosine kinases and phosphatases (20), it would be expected that the latter are under tight control or confined to specific compartments within the cell.

Many multigene families, such as those for the serine proteases (27, 28) or protein kinase (29), arose from duplications of an ancestral gene. These families can often be characterized by the degree of conservation of both the number and position of introns in the coding region (28, 30–32). The intron/exon gene organization has been described completely for CD45 (33) but only partially for LAR (18). Frequency and position of introns present in segments of the gene encoding the homologous cytoplasmic regions of CD45 and LAR are not totally conserved. For example, within CD45, there are seven introns in domain I and six in domain II, with evidence of intron sliding (34) in one of the conserved insertions. Furthermore, LAR has two fewer introns than CD45 in the PTPase-related cytoplasmic domains between exons III and VIII (18). Determination of the gene structure of T-cell PTPase may help to establish the evolutionary relationship between the low M_r and the integral membrane proteins.

Cell signaling through certain hormone and growth factor receptors, or transformation by a number of oncogenic retroviruses involves the phosphorylation of proteins on tyrosyl residues. Overexpression of a PTPase should cause a perturbation of the system in favor of the dephosphorylated state and thus may help clarify the role of protein tyrosine phosphorylation in the control of cellular processes.

We are especially grateful to Richard Olsgaard for his assistance in sequencing the cDNA described in this paper and for other

essential technical help. We thank Dr. Roger Perlmutter for providing us with the T-cell cDNA library. We are grateful to Dr. S. McKnight for his critical review of this manuscript and Carmen Westwater for typing it. This work was funded by Grants DK07902 and GM 15731 from the National Institutes of Health, the Muscular Dystrophy Association, and Howard Hughes Medical Institute. D.E.C. is supported as a Postdoctoral Fellow by the Canadian Heart Foundation.

- Charbonneau, L., Tonks, N. K., Kumar, S., Diltz, C. D., Harrylock, M., Cool, D. E., Krebs, E. G., Fischer, E. H. & Walsh, K. A. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 5252–5256.
- Streuli, M., Hall, L. R., Saga, Y., Schlossman, S. F. & Saito, H. (1987) *J. Exp. Med.* **166**, 1548–1566.
- Thomas, M. L., Barclay, A. N., Gagnon, J. & Williams, A. F. (1985) *Cell* **41**, 83–93.
- Thomas, M. L., Reynolds, P. J., Chain, A., Ben-Neriah, Y. & Trowbridge, I. S. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 5360–5363.
- Charbonneau, H., Tonks, N. K., Walsh, K. A. & Fischer, E. H. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 7182–7186.
- Tonks, N. K., Charbonneau, H., Diltz, C. D., Kumar, S., Cicirelli, M. F., Krebs, E. G., Walsh, K. A. & Fischer, E. H. (1989) *Adv. Protein Phosphatases* **5**, 149–180.
- Ledbetter, J. A., Tonks, N. K., Fischer, E. H. & Clark, E. A. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 8628–8632.
- Littman, D. R., Thomas, Y., Maddon, P. J., Chess, L. & Axel, R. (1985) *Cell* **40**, 237–246.
- Lathe, R. (1985) *J. Mol. Biol.* **183**, 1–12.
- Maniatis, T., Fritsch, E. H. & Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY).
- Sanger, F., Nicklen, S. & Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 5463–5467.
- Laemmli, U. K. (1970) *Nature (London)* **227**, 680–685.
- Cathala, G., Savouret, J. F., Mendez, B. L., Karin, M., Martial, J. A. & Baxter, J. D. (1983) *DNA* **2**, 329–335.
- Kozak, M. (1984) *Nucleic Acids Res.* **12**, 857–873.
- Proudfoot, J. M. & Brownlee, G. G. (1976) *Nature (London)* **265**, 211–214.
- Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1988) *J. Biol. Chem.* **263**, 6722–6730.
- Perry, R. P. (1976) *Annu. Rev. Biochem.* **45**, 605–629.
- Streuli, M., Krueger, N. X., Hall, L. R., Schlossman, S. F. & Saito, H. (1988) *J. Exp. Med.* **168**, 1523–1530.
- Shriner, C. L. & Brautigan, D. L. (1984) *J. Biol. Chem.* **259**, 11383–11390.
- Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1988) *J. Biol. Chem.* **263**, 6731–6737.
- Roome, J., O'Hare, T., Pilch, P. F. & Brautigan, D. L. (1988) *Biochem. J.* **256**, 493–500.
- Brunati, A. M. & Pinna, L. A. (1985) *Biochem. Biophys. Res. Comm.* **133**, 929–936.
- Tung, H. Y. L. & Reed, L. J. (1987) *Anal. Biochem.* **261**, 412–419.
- Tonks, N. K., Charbonneau, H., Diltz, C. D., Fischer, E. H. & Walsh, K. A. (1988) *Biochemistry* **27**, 8695–8701.
- Ingebritsen, T. S., Lewis, S. K., Ingebritsen, V. M., Jena, V. P., Hiriyanna, K. T., Jones, S. W. & Erikson, R. L. (1989) *Adv. Protein Phosphatases* **5**, 121–147.
- Edelman, G. M. (1988) *Biochemistry* **27**, 3533–3543.
- Neurath, H. (1984) *Science* **224**, 350–357.
- MacGillivray, R. T. A., Cool, D. E., Fung, M. R., Guinto, E. R., Keschinsky, M. L. & Van Oost, B. A. (1988) *Genet. Eng.* **10**, 265–330.
- Hanks, S. K., Quinn, A. M. & Hunter, T. (1988) *Science* **241**, 42–52.
- Doolittle, R. F. (1985) *Trends Biochem. Sci.* **10**, 233–237.
- Gilbert, W. (1985) *Science* **228**, 823–824.
- Furie, B. & Furie, B. C. (1988) *Cell* **53**, 505–518.
- Hall, L. R., Streuli, M., Schlossman, S. F. & Saito, H. (1988) *J. Immunol.* **141**, 2781–2787.
- Craik, C. S., Rutter, W. J. & Fletterick, R. (1983) *Science* **220**, 1125–1129.